207 related articles for article (PubMed ID: 36830993)
1. The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure.
Berezin AA; Obradovic Z; Fushtey IM; Berezina TA; Novikov EV; Schmidbauer L; Lichtenauer M; Berezin AE
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36830993
[TBL] [Abstract][Full Text] [Related]
2. The Effect of SGLT2 Inhibitor Dapagliflozin on Serum Levels of Apelin in T2DM Patients with Heart Failure.
Berezin AA; Fushtey IM; Berezin AE
Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35885056
[TBL] [Abstract][Full Text] [Related]
3. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
[TBL] [Abstract][Full Text] [Related]
4. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.
Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2018 Oct; 17(1):132. PubMed ID: 30296931
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Kidney Function Outcomes and Their Relation to SGLT2 Inhibitor Dapagliflozin in Patients with Type 2 Diabetes Mellitus Who Had Chronic Heart Failure.
Berezina TA; Fushtey IM; Berezin AA; Pavlov SV; Berezin AE
Adv Ther; 2024 Jan; 41(1):292-314. PubMed ID: 37935870
[TBL] [Abstract][Full Text] [Related]
6. Impact of Dapagliflozin on the Left Ventricular Diastolic Function in Diabetic Patients with Heart Failure Complicating Cardiovascular Risk Factors.
Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Intern Med; 2021; 60(15):2367-2374. PubMed ID: 34334588
[TBL] [Abstract][Full Text] [Related]
7. Adropin Predicts Chronic Kidney Disease in Type 2 Diabetes Mellitus Patients with Chronic Heart Failure.
Berezina TA; Obradovic Z; Boxhammer E; Berezin AA; Lichtenauer M; Berezin AE
J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983232
[TBL] [Abstract][Full Text] [Related]
8. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
[TBL] [Abstract][Full Text] [Related]
9. Beneficial Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Left Ventricular Function.
Shi FH; Li H; Shen L; Xu L; Ge H; Gu ZC; Lin HW; Pu J
J Clin Endocrinol Metab; 2022 Mar; 107(4):1191-1203. PubMed ID: 34791312
[TBL] [Abstract][Full Text] [Related]
10. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K;
Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543
[TBL] [Abstract][Full Text] [Related]
11. Elevated plasma levels of adropin in heart failure patients.
Lian W; Gu X; Qin Y; Zheng X
Intern Med; 2011; 50(15):1523-7. PubMed ID: 21804276
[TBL] [Abstract][Full Text] [Related]
12. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.
Solomon SD; Vaduganathan M; Claggett BL; de Boer RA; DeMets D; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Belohlavek J; Chiang CE; Willem Borleffs CJ; Comin-Colet J; Dobreanu D; Drozdz J; Fang JC; Alcocer Gamba MA; Al Habeeb W; Han Y; Cabrera Honorio JW; Janssens SP; Katova T; Kitakaze M; Merkely B; O'Meara E; Kerr Saraiva JF; Tereschenko SN; Thierer J; Vardeny O; Verma S; Vinh PN; Wilderäng U; Zaozerska N; Lindholm D; Petersson M; McMurray JJV
JACC Heart Fail; 2022 Mar; 10(3):184-197. PubMed ID: 35241246
[TBL] [Abstract][Full Text] [Related]
13. Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure.
Xanthopoulos A; Katsiadas N; Skoularigkis S; Magouliotis DE; Skopeliti N; Patsilinakos S; Briasoulis A; Triposkiadis F; Skoularigis J
Life (Basel); 2023 Aug; 13(8):. PubMed ID: 37629635
[TBL] [Abstract][Full Text] [Related]
14. Increased left atrial volume index is an independent predictor of raised serum natriuretic peptide in patients with suspected heart failure but normal left ventricular ejection fraction: Implication for diagnosis of diastolic heart failure.
Lim TK; Ashrafian H; Dwivedi G; Collinson PO; Senior R
Eur J Heart Fail; 2006 Jan; 8(1):38-45. PubMed ID: 16115798
[TBL] [Abstract][Full Text] [Related]
15. Adropin and Irisin in Patients with Cardiac Cachexia.
Kalkan AK; Cakmak HA; Erturk M; Kalkan KE; Uzun F; Tasbulak O; Diker VO; Aydin S; Celik A
Arq Bras Cardiol; 2018 Jul; 111(1):39-47. PubMed ID: 29972412
[TBL] [Abstract][Full Text] [Related]
16. Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.
Singh JS; Fathi A; Vickneson K; Mordi I; Mohan M; Houston JG; Pearson ER; Struthers AD; Lang CC
Cardiovasc Diabetol; 2016 Jul; 15():97. PubMed ID: 27422625
[TBL] [Abstract][Full Text] [Related]
17. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
Docherty KF; Anand IS; Chiang CE; Chopra VK; Desai AS; Kitakaze M; Verma S; Vinh PN; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Bengtsson O; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Langkilde AM; Jhund PS; McMurray JJV
JACC Asia; 2022 Apr; 2(2):139-153. PubMed ID: 36339117
[TBL] [Abstract][Full Text] [Related]
18. The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus.
Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
Intern Med; 2018 Aug; 57(15):2147-2156. PubMed ID: 29607968
[TBL] [Abstract][Full Text] [Related]
19. The impact of SGLT2 inhibition on imaging markers of cardiac function: A systematic review and meta-analysis.
Theofilis P; Antonopoulos AS; Katsimichas T; Oikonomou E; Siasos G; Aggeli C; Tsioufis K; Tousoulis D
Pharmacol Res; 2022 Jun; 180():106243. PubMed ID: 35523389
[TBL] [Abstract][Full Text] [Related]
20. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
